Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Molecular genetics complexity impeding research progress in breast and ovarian cancers.

Gupta I, Burney I, Al-Moundhri MS, Tamimi Y.

Mol Clin Oncol. 2017 Jul;7(1):3-14. doi: 10.3892/mco.2017.1275. Epub 2017 May 29.

2.

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.

Hassan W, Chitcholtan K, Sykes P, Garrill A.

Oncol Ther. 2016;4(2):257-274. doi: 10.1007/s40487-016-0031-1. Epub 2016 Sep 27.

3.

Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Brasseur K, GĂ©vry N, Asselin E.

Oncotarget. 2017 Jan 17;8(3):4008-4042. doi: 10.18632/oncotarget.14021. Review.

4.

Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN.

MAbs. 2016 Nov/Dec;8(8):1437-1455. Epub 2016 Aug 5. Review.

5.

Targeted therapy in ovarian cancer.

Lim HJ, Ledger W.

Womens Health (Lond). 2016 Jun;12(3):363-78. doi: 10.2217/whe.16.4. Epub 2016 May 24. Review.

6.

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.

Sui H, Shi C, Yan Z, Li H.

Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.

7.

Targeted therapies in epithelial ovarian cancer.

Dean E, El-Helw L, Hasan J.

Cancers (Basel). 2010 Feb 23;2(1):88-113. doi: 10.3390/cancers2010088.

8.

Targeting signaling pathways in epithelial ovarian cancer.

Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J.

Int J Mol Sci. 2013 May 2;14(5):9536-55. doi: 10.3390/ijms14059536. Review.

9.
10.

Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.

Gottschalk N, Kimmig R, Lang S, Singh M, Brandau S.

Int J Mol Sci. 2012;13(9):12000-16. doi: 10.3390/ijms130912000. Epub 2012 Sep 20.

11.
12.

Clinical utility of targeted treatments in the management of epithelial ovarian cancer.

Twu C, Han ES.

Biologics. 2012;6:233-44. doi: 10.2147/BTT.S29356. Epub 2012 Jul 26.

13.

Investigational agents in development for the treatment of ovarian cancer.

Westin SN, Herzog TJ, Coleman RL.

Invest New Drugs. 2013 Feb;31(1):213-29. doi: 10.1007/s10637-012-9837-3. Epub 2012 Jun 4. Review.

14.

Targeting angiogenesis in gynecologic cancers.

Zand B, Coleman RL, Sood AK.

Hematol Oncol Clin North Am. 2012 Jun;26(3):543-63, viii. doi: 10.1016/j.hoc.2012.01.009. Review.

15.

EGFR/HER-targeted therapeutics in ovarian cancer.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ.

Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Review.

16.

Monoclonal antibodies in gynecological cancer: a critical point of view.

Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M.

Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Review.

17.

Ovarian cancer: opportunity for targeted therapy.

Tagawa T, Morgan R, Yen Y, Mortimer J.

J Oncol. 2012;2012:682480. doi: 10.1155/2012/682480. Epub 2011 Dec 22.

18.

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Itamochi H.

World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209.

19.

Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A.

Clin Dev Immunol. 2010;2010:791603. doi: 10.1155/2010/791603. Epub 2011 Jan 24. Review.

20.

Therapeutic advances in women's cancers.

Carroll AR, Coleman RL, Sood AK.

Front Biosci (Schol Ed). 2011 Jan 1;3:82-97. Review.

Supplemental Content

Support Center